
Laurus Labs (LAURUSLABS) 52 Week High Streak: Second Straight Session at Rs 2,207.00
Updated: 29 Oct 2026 • 12:47 pm
Posted by:

Laurus Labs Ltd. has now set a fresh 52-week high for its second straight session, extending the Laurus Labs 52 Week High Streak that began on 28 October 2026. The stock touched Rs 2,207.00 on 29 October 2026 and last traded at Rs 2,174.00 as of 12:37 PM IST, with a cumulative change of 1.60% across the streak. According to Univest data, the price pattern is confirmed, but no company-specific catalyst is established for the continued move.
The previous close was Rs 2,184.95, the day open was Rs 2,190.00 and the day low was Rs 2,172.15, while market capitalisation stands at Rs 1,15,616.01 crore. A repeated fresh 52-week high tells a reader more than a single-day breakout, because the stock has reached a new one-year peak on each of two sessions rather than once. The sections below test that pattern against valuation, sector and peer figures.
Laurus Labs 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,174 |
| Previous Close | Rs 2,184.95 |
| Today's Move | Rs -10.95 (-0.5%) |
| Open | Rs 2,190 |
| High | Rs 2,207 |
| Low | Rs 2,172.15 |
| Market Capitalisation | Rs 1,15,616.01 crore |
Laurus Labs Ltd. (LAURUSLABS) traded at Rs 2,174 versus the previous close of Rs 2,184.95, a fall of 0.5%. The stock opened at Rs 2,190, reached a high of Rs 2,207 and touched a low of Rs 2,172.15.
Laurus Labs last traded at Rs 2,174.00 as of 29 October 2026 at 12:37 PM IST, down Rs 10.95 or 0.50% from the previous close of Rs 2,184.95. The stock touched a fresh 52-week high of Rs 2,207.00 during the session, its second straight session at a new one-year peak.
The session opened at Rs 2,190.00 and the day low stood at Rs 2,172.15, so the stock moved between Rs 2,172.15 and Rs 2,207.00, a spread of Rs 34.85. The latest traded price of Rs 2,174.00 sits Rs 1.85 above the day low and Rs 33.00 below the day high, which places it near the bottom of the day's range even though the day's high is a fresh yearly peak.
Market capitalisation is Rs 1,15,616.01 crore, a measure of company size and not a verdict on quality. The day's decline and the new 52-week high are two separate facts, and both are shown here exactly as reported, with no cause attached to either.
What the Repeated 52-Week Highs Show
The repeated highs show that Laurus Labs has traded at a new one-year peak on 28 October 2026 and again on 29 October 2026. According to Univest data, the price pattern is confirmed, but no company-specific catalyst is established, so the pattern describes what the price did and does not explain why.
A single fresh high records one breakout. Two in a row record that the one-year peak was raised again on the second session, and the latest level is Rs 2,207.00. For readers following Stocks Hitting 52 Week Highs, the useful questions are what that peak sits against and what could change it.
The latest peak is Rs 2,207.00, the day open is Rs 2,190.00 and the previous close is Rs 2,184.95, so the recent range is visible in three figures. Whether the streak extends to a third straight session is a question for the next trading day, and no outcome is implied. The valuation sections that follow show where the multiples sit once this move is included.
Laurus Labs Ltd. (LAURUSLABS) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,15,616.01 crore |
| P/E Ratio | 107.97x |
| P/B Ratio | 20.94x |
| ROE | 18.31% |
| ROCE | 18.2% |
| EPS | Rs 20.24 |
| Book Value Per Share | Rs 104.37 |
| Dividend Yield | 0.09% |
Laurus Labs Ltd. (LAURUSLABS) fundamental metrics show P/E 107.97x, P/B 20.94x, ROE 18.31%, ROCE 18.2%. These figures provide context only and are not a buy or sell signal.
Laurus Labs Ltd. has a market capitalisation of Rs 1,15,616.01 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 107.97x, P/B at 20.94x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 18.31% and ROCE of 18.2%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 20.24, book value per share of Rs 104.37, dividend yield of 0.09%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.53x, median ROE of 11.22%, median ROCE of 13.1%. Taken together, they outline the fundamentals rather than a view on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 107.97x |
| Benchmark Median P/E | 31.53x |
| Benchmark Average P/E | 45.86x |
| Benchmark P/E Range | 3.21x to 598.47x |
| Company P/B Ratio | 20.94x |
| Benchmark Median P/B | 2.74x |
| Company ROE | 18.31% |
| Benchmark Median ROE | 11.22% |
| Company ROCE | 18.2% |
| Benchmark Median ROCE | 13.1% |
| Company Market Capitalisation | Rs 1,15,616.01 crore |
| Benchmark Median Market Cap | Rs 711.9 crore |
Laurus Labs Ltd. (LAURUSLABS) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Laurus Labs Ltd. (LAURUSLABS) has a P/E ratio of 107.97x, which is above the benchmark median of 31.53x, a difference of +242.44%. On its own, the P/E gap is a valuation reference point, not a trading call.
Laurus Labs Ltd. (LAURUSLABS) has a ROE of 18.31%, which is above the benchmark median of 11.22%, a difference of +63.19%. Laurus Labs Ltd. (LAURUSLABS) has a ROCE of 18.2%, which is above the benchmark median of 13.1%, a difference of +38.93%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,16,408.7 | 25.9 | 4.34 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,09,062.53 | 37.93 | 3.1 | 11.83 | 16 |
| Dr. Reddy's Laboratories Ltd. | DRREDDY | 1,08,925.78 | 39.81 | 2.87 | 11.69 | 13.75 |
| Mankind Pharma Ltd. | MANKIND | 1,03,286.06 | 45.74 | 5.83 | 12.69 | 13.24 |
| Aurobindo Pharma Ltd. | AUROPHARMA | 93,959.21 | 25.42 | 2.42 | 9.93 | 12.76 |
Laurus Labs Ltd. (LAURUSLABS) has a P/E ratio of 107.97x compared with the displayed peer median of 37.93x. This peer read is a relative benchmark rather than a trading signal. Its ROE of 18.31% compares with a peer median of 11.83% across the companies shown in the table. ROCE stood at 18.2% versus the displayed peer median of 13.75%, providing a capital-efficiency comparison. Laurus Labs Ltd. (LAURUSLABS) has a market capitalisation of Rs 1,15,616.01 crore. Among the 5 peers shown, 1 has a larger market capitalisation.
Why Investors Are Watching Laurus Labs
- Laurus Labs has set a fresh 52-week high for its second straight session, touching Rs 2,207.00.
- The stock last traded at Rs 2,174.00, down 0.50% from the previous close of Rs 2,184.95.
- P/E of 107.97 is 242.44% above the same-industry median of 31.53.
- ROE of 18.31% and ROCE of 18.20% are above the benchmark medians of 11.22% and 13.10%.
- Market cap of Rs 1,15,616.01 crore is larger than four of the five peers compared.
About Laurus Labs
Laurus Labs Ltd. trades on NSE under the symbol LAURUSLABS and belongs to the Healthcare sector, in the Pharmaceuticals & Drugs industry. For a reader following the streak, this classification matters because the sector and peer figures above are drawn from that same industry group of 198 companies.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
How many sessions has Laurus Labs set a fresh 52-week high?
Ans. Laurus Labs has set a fresh 52-week high for its second straight session, the first on 28 October 2026 and the second on 29 October 2026, when the stock touched Rs 2,207.00. That is the Laurus Labs 52 Week High Streak so far.
What is the Laurus Labs share price today?
Ans. As of 29 October 2026 at 12:37 PM IST, Laurus Labs last traded at Rs 2,174.00, down Rs 10.95 or 0.50% from the previous close of Rs 2,184.95. The day high and the 52-week high both stand at Rs 2,207.00.
What is the cumulative change across the Laurus Labs streak?
Ans. According to latest Univest data, the cumulative change across the streak is 1.60%. The stock is down 0.50% on the day, so the cumulative figure and today's move are separate facts, and neither one establishes a company-specific catalyst.
Is a company-specific catalyst confirmed for the repeated highs?
Ans. According to Univest data, the price pattern is confirmed, but no company-specific catalyst is established. The stock set a fresh 52-week high on two straight sessions, and the figures describe what the price did without explaining why it moved.
What is the market cap of Laurus Labs?
Ans. The Laurus Labs market cap is Rs 1,15,616.01 crore according to latest Univest data. That compares with a benchmark median of Rs 711.90 crore across the 198 companies in the same Pharmaceuticals & Drugs industry group.
What are the P/E and P/B ratios of Laurus Labs?
Ans. Laurus Labs has a P/E ratio of 107.97 and a P/B ratio of 20.94. The same-industry median P/E is 31.53 and the median P/B is 2.74, so both multiples sit well above the benchmark medians after the streak.
What are the ROE and ROCE of Laurus Labs?
Ans. Laurus Labs reports an ROE of 18.31% and an ROCE of 18.20%. Both are above the same-industry medians of 11.22% and 13.10%, which means the company is ahead of the typical company in its industry group on these two measures.
What are the EPS, book value and dividend yield of Laurus Labs?
Ans. EPS is Rs 20.24, book value per share is Rs 104.37 and dividend yield is 0.09%. Dividend yield is a historical figure relative to the current price and does not promise any future payout, so it works as background context.
Track Laurus Labs Share Price on Univest
Use Laurus Labs Ltd. (LAURUSLABS) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Readers can follow the Laurus Labs 52 Week High Streak on Univest, along with the live share price, P/E ratio, P/B ratio, ROE, ROCE, EPS, book value, dividend yield and 52-week levels. Univest also places each ratio beside the same-industry benchmark, so the next session can be read against the figures in this article.
Recent Articles

Kalyan Jewellers Share Price Rally: Stock Gains About 42% in 11 Sessions After Rs 427 Crore Q2 Profit, Hits Near Two-Year High and Trades at Rs 708.15 on 16 November 2026 as UBS and Jefferies Raise Targets
16 November 2026

Tata Motors PV vs Eicher Motors After Q2: TMPV Falls 8.7% to Rs 262 on a Rs 5,451 Crore Loss and JLR Guidance Cut While Eicher Posts Record Revenue and a 15% Profit Rise
16 November 2026

Belrise Industries Share Price Jumps 9% to Rs 235 After Q2 PAT Rises 25%: Fresh H-One India Merger, Electronics Entry and Aerospace Orders Drive a Spike of up to 12.4% on 16 November 2026
16 November 2026

Sebi Trading Terminal Rules: What Biometrics, Geotagging and MAC Address Mapping Could Mean for Brokers, Authorised Persons and Traders as the Regulator Targets Terminal Misuse
16 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Kalyan Jewellers Share Price Rally: Stock Gains About 42% in 11 Sessions After Rs 427 Crore Q2 Profit, Hits Near Two-Year High and Trades at Rs 708.15 on 16 November 2026 as UBS and Jefferies Raise Targets
Tata Motors PV vs Eicher Motors After Q2: TMPV Falls 8.7% to Rs 262 on a Rs 5,451 Crore Loss and JLR Guidance Cut While Eicher Posts Record Revenue and a 15% Profit Rise
Belrise Industries Share Price Jumps 9% to Rs 235 After Q2 PAT Rises 25%: Fresh H-One India Merger, Electronics Entry and Aerospace Orders Drive a Spike of up to 12.4% on 16 November 2026
Sebi Trading Terminal Rules: What Biometrics, Geotagging and MAC Address Mapping Could Mean for Brokers, Authorised Persons and Traders as the Regulator Targets Terminal Misuse
Ola Electric vs Ather Energy After Q2: Ather's Rs 1.26 Crore Profit and 63% Revenue Growth Against Ola's Rs 362 Crore Loss and 39% Revenue Fall, and What the Share Prices Imply on 16 November 2026

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





